Table 3.
Characteristics of studies evaluating the efficacy and safety of DEX implant in Infectious Uveitis.
| Author (Year) | Design | Etiology | Eyes (n) | DEX Injections | Follow up (Months) | Main Outcomes | Complications |
|---|---|---|---|---|---|---|---|
| Fonollosa (2016) [118] | Retrospective case series | Herpes simplex virus-type 1, Varicella-Zoster virus, Treponema Pallidum, Brucella Mellitensis, Borrelia Burgdorferi, Toxoplasma Gondii, Cytomegalovirus |
8 | Repeated (except 2 eyes) | 6–31 | Resolved ME, Improved BCVA, No reactivation of infectious disease | Transient IOP increase (1 eye) |
| Agarwal (2018) [119] | Retrospective case series | Mycobacterium tuberculosis | 19 | Single | 3–4 | Decreased ME, vitritis and progression of choroiditis lesions | Transient IOP increase (4 eyes), Cataract progression (2 eyes) |
| Jain (2018) [120] | Retrospective case series | Mycobacterium tuberculosis | 9 | Repeated | 6–24 | Stabilization of inflammatory lesions, Increased BCVA | IOP increase (2 eyes) |
| Lautredou (2018) [121] | Case report | Treponema pallidum and HIV | 1 | Repeated | 15 | Resolved ME, Improved BCVA | None |
| Majumder (2019) [122] | Case report | Treponema pallidum and HIV | 1 | Repeated | 4 | Resolved ME, Improved BCVA | Transient IOP increase |
| Majumder (2016) [123] | Retrospective case series | Herpes Virus | 4 | Repeated | 6–24 | Resolved ME, Improved BCVA, No reactivation of retinitis | None |
DEX: Dexamethasone intravitreal implant, IOP: Intraocular pressure, BCVA: Best corrected visual acuity, HIV: Human immunodeficiency virus.